CCL2 and triple-negative breast carcinoma: These findings suggest that IFI35 inhibits tumor progression, and in a separate study on triple-negative breast cancer, we observed that high expression of IFI35 promotes CCL2 secretion, which leads to the infiltration of myeloid-derived suppressor cells (MDSC) and dysfunction of anti-tumor CD8+ T cells, thereby limiting its anti-tumor effects.